Results 51 to 60 of about 541,695 (230)
Blood, 2019 Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance.
C. Dinardo +15 more
semanticscholar +1 more source
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
Nature Communications, 2020 Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization of clonal architecture is essential to understand the evolutionary history of tumor development and its association with treatment ...
Kiyomi Morita +37 more
semanticscholar +1 more source
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]
, 2002 FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Bowen, D.T. +5 more
core +1 more source
Low expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia
Tumor Biology, 2017 Dysregulation of NKD1 has been identified in several solid tumors. However, the status of NKD1 expression and its clinical implication in acute myeloid leukemia remain largely elusive.
Jing-dong Zhou +10 more
doaj +1 more source
Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.
Blood, 2020 Despite recent advancements, approximately 50% of patients with acute myeloid leukemia (AML) do not respond to induction therapy (primary induction failure, PIF) or relapse after
G. Uy +47 more
semanticscholar +1 more source
miRNAs in acute myeloid leukemia
Oncotarget, 2016 MicroRNAs (miRNAs) are small, non-coding RNAs found throughout the eukaryotes that control the expression of a number of genes involved in commitment and differentiation of hematopoietic stem cells and tumorigenesis. Widespread dysregulation of miRNAs have been found in hematological malignancies, including human acute myeloid leukemia (AML).
Xia Li +4 more
openaire +4 more sources
Genomics of Acute Myeloid Leukemia [PDF]
The Cancer Journal, 2011 The acute myeloid leukemia (AML) genome has been the subject of intensive research over the past 4 decades. New technologies, enabling characterization of the AML genome at increased resolution, have revealed deeper layers of complexity that have provided insights into the biological basis of this disease, nominated targets for therapy, and identified ...
Elaine R. Mardis, Timothy A. Graubert
openaire +3 more sources
Biological aspects of mTOR in leukemia [PDF]
, 2018 The mammalian target of rapamycin (mTOR) is a central processor of intra-and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival.
Bianchi, Mp +5 more
core +1 more source
Haematologica, 2018 Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate - acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option.
Dalila Salvatore +16 more
doaj +1 more source
Treatment of Relapsed Acute Myeloid Leukemia
Current Treatment Options in Oncology, 2020 Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40–50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse
F. Thol, A. Ganser
semanticscholar +1 more source